Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease

BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Altho...

Full description

Saved in:
Bibliographic Details
Published inInflammatory bowel diseases Vol. 16; no. 7; pp. 1097 - 1107
Main Authors Beltrán, Caroll J., Núñez, Lucía E., Díaz-Jiménez, David, Farfan, Nancy, Candia, Enzo, Heine, Claudio, López, Francisco, González, María Julieta, Quera, Rodrigo, Hermoso, Marcela A.
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford University Press 01.07.2010
Wiley Subscription Services, Inc., A Wiley Company
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).MethodsExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ResultsST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.ConclusionsThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010
AbstractList Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD). Methods: Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence. Results: ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution. Conclusions: The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010.
ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD). Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence. ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution. The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases.
ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).BACKGROUNDST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.METHODSExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.RESULTSST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases.CONCLUSIONSThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases.
Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL‐33 membrane receptor and belongs to the IL‐1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL‐33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL‐33 in inflammatory bowel disease (IBD). Methods: Expression of ST2 and IL‐33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse‐transcription polymerase chain reaction (RT‐PCR) and enzyme‐linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL‐33 protein by ELISA. Intestinal mucosa localization of ST2 and IL‐33 was conducted by immunofluorescence. Results: ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL‐33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL‐33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL‐33 showed cytoplasm‐nuclear redistribution. Conclusions: The novel association between the ST2/IL‐33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010
BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).MethodsExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ResultsST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.ConclusionsThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010
Author Beltrán, Caroll J.
Farfan, Nancy
Heine, Claudio
Hermoso, Marcela A.
González, María Julieta
Quera, Rodrigo
López, Francisco
Núñez, Lucía E.
Díaz-Jiménez, David
Candia, Enzo
Author_xml – sequence: 1
  givenname: Caroll J.
  surname: Beltrán
  fullname: Beltrán, Caroll J.
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
– sequence: 2
  givenname: Lucía E.
  surname: Núñez
  fullname: Núñez, Lucía E.
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
– sequence: 3
  givenname: David
  surname: Díaz-Jiménez
  fullname: Díaz-Jiménez, David
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
– sequence: 4
  givenname: Nancy
  surname: Farfan
  fullname: Farfan, Nancy
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
– sequence: 5
  givenname: Enzo
  surname: Candia
  fullname: Candia, Enzo
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
– sequence: 6
  givenname: Claudio
  surname: Heine
  fullname: Heine, Claudio
  organization: 3Laboratory of Oncology and Molecular Genetics, Colorectal Surgery Unit, Las Condes Clinic, Santiago, Chile
– sequence: 7
  givenname: Francisco
  surname: López
  fullname: López, Francisco
  organization: 3Laboratory of Oncology and Molecular Genetics, Colorectal Surgery Unit, Las Condes Clinic, Santiago, Chile
– sequence: 8
  givenname: María Julieta
  surname: González
  fullname: González, María Julieta
  organization: 4Cell and Molecular Biology Program, Biomedical Sciences Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile
– sequence: 9
  givenname: Rodrigo
  surname: Quera
  fullname: Quera, Rodrigo
  organization: 5Gastroenterology Unit, Santiago, Chile
– sequence: 10
  givenname: Marcela A.
  surname: Hermoso
  fullname: Hermoso, Marcela A.
  organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20014018$$D View this record in MEDLINE/PubMed
BookMark eNqFkT1PwzAQhi1URGlh4A8gD0iIIa0dJ04yQvmqVImBsrBETnJRjZK42A5V-PWYfjAgUc7Dna3nvbPuHaBeoxpA6IySESXEH8usGPmURuEBOqYh414QB0HP1SSKPZIkcR8NjHlzqDvJEer7hNCA0PgYvU4WQovcgpafwkrVYFViuwDcqA-o8PPcH09nHmPYdMZCjWWDl46Dxhq8knbhHspK1LWwSnc4UysnKqQBYeAEHZaiMnC6zUP0cn83nzx6s6eH6eR65uWBT0IvyxOIMr_gNCoZ5X6Z5QxCkpehH0MiOMkKEgZcMAGFuwYJKXgchFyQKOQsLtkQXW76LrV6b8HYtJYmh6oSDajWpJGD3aQk_p9kLihjiSPPt2Sb1VCkSy1robt0tzgHXG2AXCtjNJQ_CCXptympMyVdm-LY8S82l3a9bKuFrPYpVrKC7u_W6fTmdqe42ChUu9zzlS-gCacn
CitedBy_id crossref_primary_10_1080_14712598_2020_1733964
crossref_primary_10_1155_2018_1827901
crossref_primary_10_1182_blood_2014_10_606830
crossref_primary_10_1016_j_ajg_2024_01_002
crossref_primary_10_1093_ajcp_aqv082
crossref_primary_10_1038_srep35403
crossref_primary_10_1111_ctr_13349
crossref_primary_10_1111_cts_13442
crossref_primary_10_3109_00365521_2016_1101245
crossref_primary_10_1155_2013_142492
crossref_primary_10_1007_s10753_011_9379_4
crossref_primary_10_3389_fimmu_2018_02432
crossref_primary_10_1186_2045_3701_4_72
crossref_primary_10_1189_jlb_3RU1114_563R
crossref_primary_10_1097_MEG_0000000000001490
crossref_primary_10_1136_gutjnl_2011_301785
crossref_primary_10_1007_s00262_014_1624_x
crossref_primary_10_1038_s41573_025_01158_9
crossref_primary_10_1155_2017_6592139
crossref_primary_10_1111_j_1365_2222_2011_03867_x
crossref_primary_10_1016_j_prerep_2024_100002
crossref_primary_10_1159_000437327
crossref_primary_10_1124_jpet_114_222505
crossref_primary_10_2492_inflammregen_35_069
crossref_primary_10_1016_j_jss_2019_05_057
crossref_primary_10_1038_s41598_017_10465_0
crossref_primary_10_1038_s41598_021_89119_1
crossref_primary_10_3389_fimmu_2017_00979
crossref_primary_10_4103_ejdv_ejdv_37_21
crossref_primary_10_1073_pnas_1803613115
crossref_primary_10_1152_ajpregu_00300_2022
crossref_primary_10_1155_2018_3048941
crossref_primary_10_1111_cei_12896
crossref_primary_10_1038_mi_2016_14
crossref_primary_10_3389_fimmu_2025_1533335
crossref_primary_10_3389_fimmu_2019_01394
crossref_primary_10_3390_ijms24010623
crossref_primary_10_1111_imr_12974
crossref_primary_10_1128_IAI_02908_14
crossref_primary_10_3389_fimmu_2020_581445
crossref_primary_10_1111_jcmm_16297
crossref_primary_10_1073_pnas_1422445112
crossref_primary_10_2353_ajpath_2010_100378
crossref_primary_10_1016_j_jtauto_2019_100011
crossref_primary_10_1016_j_amjcard_2015_01_035
crossref_primary_10_1093_discim_kyac006
crossref_primary_10_1136_postgradmedj_2012_303461rep
crossref_primary_10_1152_ajpgi_00280_2022
crossref_primary_10_1016_j_scitotenv_2018_06_329
crossref_primary_10_1586_erm_12_128
crossref_primary_10_3389_fimmu_2016_00695
crossref_primary_10_1155_2019_7947596
crossref_primary_10_1111_ajt_13542
crossref_primary_10_1002_eji_201041135
crossref_primary_10_1128_IAI_01307_12
crossref_primary_10_1016_j_semcancer_2019_05_001
crossref_primary_10_1016_j_lfs_2017_08_010
crossref_primary_10_1128_mBio_00383_13
crossref_primary_10_1172_JCI88625
crossref_primary_10_2119_molmed_2011_00428
crossref_primary_10_1177_1756283X11410770
crossref_primary_10_1007_s00535_022_01936_x
crossref_primary_10_1155_2014_587376
crossref_primary_10_1016_j_cyto_2013_02_026
crossref_primary_10_1016_j_cca_2014_09_021
crossref_primary_10_1093_ibd_izae129
crossref_primary_10_1016_j_autrev_2019_03_012
crossref_primary_10_1016_j_intimp_2023_110653
crossref_primary_10_1016_j_jcmgh_2015_01_006
crossref_primary_10_1074_jbc_M116_769422
crossref_primary_10_1002_ibd_21638
crossref_primary_10_1021_acsptsci_3c00122
crossref_primary_10_1080_14767058_2018_1548601
crossref_primary_10_1016_j_cbi_2020_109315
crossref_primary_10_1016_j_phrs_2013_06_007
crossref_primary_10_1189_jlb_0810470
crossref_primary_10_3892_ol_2016_4626
crossref_primary_10_1038_s41598_017_00840_2
crossref_primary_10_1136_gutjnl_2019_319850
crossref_primary_10_3389_fimmu_2019_00364
crossref_primary_10_1186_s12876_016_0520_6
crossref_primary_10_3389_fimmu_2021_669787
crossref_primary_10_1016_j_lfs_2023_121868
crossref_primary_10_1371_journal_pone_0062144
crossref_primary_10_3390_ijms18102020
crossref_primary_10_1016_j_cyto_2018_08_009
crossref_primary_10_3389_fimmu_2019_00647
crossref_primary_10_1038_mi_2013_124
crossref_primary_10_4049_jimmunol_1201373
crossref_primary_10_1111_bph_13535
crossref_primary_10_1097_MIB_0000000000000512
crossref_primary_10_1177_2050640618792819
crossref_primary_10_1155_2014_423957
crossref_primary_10_18632_oncotarget_25768
crossref_primary_10_1152_ajplung_00305_2014
crossref_primary_10_3390_ijms22115792
crossref_primary_10_2310_JIM_0b013e31826d8fcb
crossref_primary_10_1016_j_biopha_2021_111902
crossref_primary_10_15252_embj_2023113796
crossref_primary_10_3389_fimmu_2018_01700
crossref_primary_10_5217_ir_2018_16_1_26
crossref_primary_10_1038_s41385_019_0138_4
crossref_primary_10_1007_s11882_016_0652_3
crossref_primary_10_1097_MIB_0b013e3182a8759a
crossref_primary_10_1371_journal_pone_0277576
crossref_primary_10_1136_gutjnl_2012_303920
crossref_primary_10_1007_s12028_021_01284_3
crossref_primary_10_1016_j_cyto_2012_02_008
crossref_primary_10_1016_j_gene_2022_146478
crossref_primary_10_1093_ibd_izab034
crossref_primary_10_1155_2013_608187
crossref_primary_10_1136_jim_2016_000062
crossref_primary_10_1155_2017_4810258
crossref_primary_10_3748_wjg_v20_i30_10262
crossref_primary_10_1007_s11030_021_10359_4
crossref_primary_10_1038_s41467_023_37849_3
crossref_primary_10_3389_fimmu_2018_02506
crossref_primary_10_1016_j_ijpharm_2023_123206
crossref_primary_10_1038_s41467_025_57879_3
crossref_primary_10_3390_ijms232113242
crossref_primary_10_1016_j_crohns_2013_12_021
crossref_primary_10_3389_fimmu_2019_02449
crossref_primary_10_1007_s11725_015_0608_4
crossref_primary_10_3389_fimmu_2023_1158323
crossref_primary_10_1073_pnas_1307321110
crossref_primary_10_1038_s41598_017_05716_z
crossref_primary_10_1586_1744666X_2013_814428
crossref_primary_10_1016_j_celrep_2016_04_049
crossref_primary_10_1111_bph_13712
crossref_primary_10_1016_j_bcp_2023_115787
crossref_primary_10_1016_j_cyto_2017_06_017
crossref_primary_10_1371_journal_pone_0052252
crossref_primary_10_1021_acs_molpharmaceut_1c00002
crossref_primary_10_1097_MIB_0000000000000532
crossref_primary_10_1111_imm_12111
crossref_primary_10_1002_slct_202403179
crossref_primary_10_3390_diagnostics12102344
crossref_primary_10_1016_j_cytogfr_2015_07_017
crossref_primary_10_1038_s41598_021_82096_5
crossref_primary_10_1136_gutjnl_2023_329963
crossref_primary_10_1177_1756284819869141
crossref_primary_10_1016_j_cytogfr_2019_04_004
crossref_primary_10_1111_ctr_14616
crossref_primary_10_3390_ijms26010121
crossref_primary_10_1177_1721727X1401200209
crossref_primary_10_1093_ibd_izae292
crossref_primary_10_1159_000445133
crossref_primary_10_1111_coa_13647
crossref_primary_10_1007_s00535_010_0245_1
crossref_primary_10_1016_j_ajpath_2015_11_028
crossref_primary_10_1016_j_ejphar_2022_175379
crossref_primary_10_1016_j_jaci_2016_09_049
crossref_primary_10_3390_biomedicines12112562
crossref_primary_10_1097_01_MIB_0000437616_37000_41
crossref_primary_10_1007_s00535_014_0982_7
crossref_primary_10_1007_s12079_022_00695_x
crossref_primary_10_1038_s41374_019_0329_3
crossref_primary_10_1152_physrev_00005_2021
crossref_primary_10_1016_j_intimp_2022_108887
crossref_primary_10_1177_09636897231177377
crossref_primary_10_3389_fmed_2017_00126
crossref_primary_10_1038_nature13577
crossref_primary_10_1155_2015_864597
crossref_primary_10_1016_j_cca_2019_07_033
crossref_primary_10_1016_j_imlet_2015_10_004
crossref_primary_10_1038_s41598_020_60155_7
crossref_primary_10_1186_s13317_019_0110_z
crossref_primary_10_1016_j_bcp_2018_01_010
crossref_primary_10_1016_j_imbio_2011_10_023
crossref_primary_10_1016_j_imbio_2015_06_003
crossref_primary_10_1080_2162402X_2015_1062966
crossref_primary_10_1371_journal_pone_0056866
crossref_primary_10_1016_j_intimp_2017_02_006
crossref_primary_10_1111_imm_12174
crossref_primary_10_1128_IAI_00707_20
crossref_primary_10_3389_fimmu_2019_01091
crossref_primary_10_2310_JIM_0b013e31828deed2
crossref_primary_10_1038_mi_2011_22
crossref_primary_10_1002_pmic_201400303
crossref_primary_10_1186_1755_1536_5_18
crossref_primary_10_1007_s10753_018_0776_9
crossref_primary_10_1016_j_imlet_2016_08_007
crossref_primary_10_1111_1348_0421_12381
crossref_primary_10_1155_2022_1358858
crossref_primary_10_1038_s41598_025_91202_w
crossref_primary_10_1016_j_cyto_2012_06_014
crossref_primary_10_1212_WNL_0000000000206764
crossref_primary_10_1016_j_intimp_2015_01_012
crossref_primary_10_3389_fimmu_2017_00475
Cites_doi 10.1016/j.immuni.2009.05.007
10.2353/ajpath.2008.080014
10.1016/j.bbrc.2006.10.166
10.1055/s-2008-1039044
10.1016/j.cyto.2007.09.013
10.1074/jbc.M704916200
10.1007/s00134-004-2184-x
10.1016/0167-5699(94)90217-8
10.4049/jimmunol.180.4.2443
10.1073/pnas.0606854104
10.1073/pnas.0812690106
10.1002/eji.200636520
10.1038/mp.2009.10
10.1038/labinvest.3700663
10.1016/S0140-6736(07)60750-8
10.1164/ajrccm.164.2.2008120
10.1006/bbrc.1997.6810
10.1172/JCI19836
10.1378/chest.124.4.1206
10.1164/rccm.200805-666OC
10.1073/pnas.0705939104
10.1016/j.immuni.2005.09.015
10.1016/j.bbrc.2009.07.018
10.1002/art.24305
10.1016/j.jacc.2008.07.042
10.4067/S0034-98872008000300014
10.1016/j.cyto.2007.11.001
10.1016/0014-5793(89)81679-5
10.1006/bbrc.2001.5090
10.4049/jimmunol.178.9.5859
10.1074/jbc.M901744200
10.4049/jimmunol.173.1.145
10.1006/bbrc.1999.1469
10.1155/2005/269076
10.1684/ecn.2009.0142
10.1084/jem.20071868
ContentType Journal Article
Copyright Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. 2009
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
Copyright_xml – notice: Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. 2009
– notice: Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QL
7T5
C1K
H94
DOI 10.1002/ibd.21175
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1536-4844
EndPage 1107
ExternalDocumentID 20014018
10_1002_ibd_21175
IBD21175
10.1002/ibd.21175
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GrantInformation_xml – fundername: FONDECYT
  funderid: 1070954; OAIC 167/06
GroupedDBID ---
.Z2
0R~
1OC
3WU
4.4
48X
53G
5GY
5VS
5WD
66C
7O~
8-0
8-1
8UM
AAAXR
AABZA
AACZT
AAKAS
AAPQZ
AAPXW
AARHZ
AARTV
AAUAY
AAVAP
AAYEP
ABBUW
ABDFA
ABEJV
ABGNP
ABJNI
ABNHQ
ABOCM
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVJ
ABXVV
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACUTJ
ACWDW
ACWRI
ACXNZ
ACXQS
ACYHN
ADBBV
ADBIZ
ADGZP
ADIPN
ADQBN
ADRTK
ADVEK
ADZCM
AENEX
AETBJ
AFBPY
AFFZL
AFOFC
AFTRI
AFXAL
AFZJQ
AGINJ
AGQXC
AGUTN
AHMBA
AHMMS
AIJEX
AIZYK
AJAOE
AJEEA
AJNYG
ALMA_UNASSIGNED_HOLDINGS
ATGXG
AWKKM
BAYMD
BCRHZ
BEYMZ
BOYCO
BTRTY
C45
CDBKE
CS3
DAKXR
DR2
DU5
E.X
E3Z
EBS
EJD
ENERS
EX3
F5P
FECEO
FL-
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H0~
HZ~
IN~
IX1
KBUDW
KOP
KSI
KSN
LAW
LH4
LW6
MHKGH
NNB
NOMLY
NOYVH
NU-
NVLIB
N~7
N~B
O9-
OAUYM
OCZFY
ODMLO
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
PAFKI
PQQKQ
QRW
ROL
ROX
RUSNO
RX1
S4S
TEORI
V2E
W99
WOW
XV2
YAYTL
YKOAZ
YXANX
ZFV
31~
8F7
AAJQQ
AAPGJ
AAUQX
AAWDT
ACFRR
ACZBC
AFUWQ
AFYAG
AGKRT
AGMDO
AHRYX
APJGH
AQDSO
AQKUS
AVNTJ
EIHJH
H13
IAO
IHR
ITC
MBLQV
OCUKA
ORVUJ
TMA
WOQ
Y6R
7X7
88E
8FI
8FJ
AAYXX
ABUWG
ADNBA
AEMQT
AFKRA
AGORE
AJNCP
ALXQX
BENPR
CCPQU
CITATION
FYUFA
HMCUK
JXSIZ
M1P
PHGZM
PHGZT
PJZUB
PPXIY
PSQYO
UKHRP
AFFQV
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QL
7T5
C1K
H94
ID FETCH-LOGICAL-c4205-bc9e7b2d617f3162fbc3e50cf528e9a60bd0546a3aed9a6490d68456a075638f3
IEDL.DBID DR2
ISSN 1078-0998
1536-4844
IngestDate Fri Jul 11 04:38:53 EDT 2025
Mon Jul 21 11:42:26 EDT 2025
Wed Feb 19 02:41:14 EST 2025
Sun Aug 03 02:35:16 EDT 2025
Thu Apr 24 22:54:44 EDT 2025
Wed Jan 22 17:05:15 EST 2025
Sat Feb 08 08:13:08 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords ST2
Crohn's disease
ulcerative colitis
IL-33
inflammatory bowel disease
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4205-bc9e7b2d617f3162fbc3e50cf528e9a60bd0546a3aed9a6490d68456a075638f3
Notes The last 2 authors share senior authorship.
The first 3 authors contributed equally to the article.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink http://americanae.aecid.es/americanae/es/registros/registro.do?tipoRegistro=MTD&idBib=3272597
PMID 20014018
PQID 733331339
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_745642098
proquest_miscellaneous_733331339
pubmed_primary_20014018
crossref_primary_10_1002_ibd_21175
crossref_citationtrail_10_1002_ibd_21175
wiley_primary_10_1002_ibd_21175_IBD21175
oup_primary_10_1002_ibd_21175
PublicationCentury 2000
PublicationDate July 2010
PublicationDateYYYYMMDD 2010-07-01
PublicationDate_xml – month: 07
  year: 2010
  text: July 2010
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Hoboken
– name: England
PublicationTitle Inflammatory bowel diseases
PublicationTitleAlternate Inflamm Bowel Dis
PublicationYear 2010
Publisher Oxford University Press
Wiley Subscription Services, Inc., A Wiley Company
Publisher_xml – name: Oxford University Press
– name: Wiley Subscription Services, Inc., A Wiley Company
References 2007; 104
1997; 235
2007; 369
2001; 164
2009; 20
2001; 284
2007; 282
2005; 133
1989; 258
2009; 60
1999; 264
2009; 179
2008; 205
2006; 351
2008; 52
2005; 23
2007; 37
2008; 180
2004; 30
2009; 14
2007; 178
2009; 57
2005; 19
2004; 113
2009; 31
2004; 173
2006; 69
2009; 387
1994; 15
2008; 136
2008; 41
2007; 40
2009; 284
2007; 87
2003; 124
2008; 173
2009; 106
Schmitz (2025060906215214600_R11-7) 2005; 23
Kumar (2025060906215214600_R24-7) 1997; 235
Fuss (2025060906215214600_R28-7) 2004; 113
Chapuis (2025060906215214600_R16-7) 2009; 14
Moulin (2025060906215214600_R25-7) 2007; 40
Kuchler (2025060906215214600_R27-7) 2008; 173
Carriere (2025060906215214600_R12-7) 2007; 104
Leung (2025060906215214600_R18-7) 2004; 173
Baumgart (2025060906215214600_R1-7) 2007; 369
Cayrol (2025060906215214600_R33-7) 2009; 106
Rehman (2025060906215214600_R7-7) 2008; 52
Kuroiwa (2025060906215214600_R23-7) 2001; 284
Tominaga (2025060906215214600_R10-7) 1999; 264
Iikura (2025060906215214600_R30-7) 2007; 87
Palmer (2025060906215214600_R13-7) 2009; 60
Verstege (2025060906215214600_R37-7) 2006; 69
Yin (2025060906215214600_R21-7) 2006; 351
Fichtner-Feigl (2025060906215214600_R31-7) 2007; 178
Szerafin (2025060906215214600_R19-7) 2009; 57
Mangan (2025060906215214600_R15-7) 2007; 37
Tominaga (2025060906215214600_R4-7) 1989; 258
Kearley (2025060906215214600_R14-7) 2009; 179
Miller (2025060906215214600_R17-7) 2008; 205
Colotta (2025060906215214600_R26-7) 1994; 15
Brunner (2025060906215214600_R9-7) 2004; 30
Hayakawa (2025060906215214600_R20-7) 2007; 282
Luthi (2025060906215214600_R36-7) 2009; 31
Sepulveda (2025060906215214600_R2-7) 2008; 136
Beltran (2025060906215214600_R3-7) 2009; 20
Becerra (2025060906215214600_R8-7) 2008; 41
Figueroa (2025060906215214600_R38-7) 2005; 133
Ali (2025060906215214600_R29-7) 2007; 104
Oshikawa (2025060906215214600_R5-7) 2001; 164
Silverberg (2025060906215214600_R22-7) 2005; 19
Talabot-Ayer (2025060906215214600_R35-7) 2009; 284
Hayakawa (2025060906215214600_R34-7) 2009; 387
Tajima (2025060906215214600_R6-7) 2003; 124
Humphreys (2025060906215214600_R32-7) 2008; 180
References_xml – volume: 69
  start-page: 406
  year: 2006
  end-page: 416
  article-title: Apoptosis as a therapeutic paradigm in inflammatory bowel diseases
  publication-title: Acta Gastroenterol Belg.
– volume: 178
  start-page: 5859
  year: 2007
  end-page: 5870
  article-title: Induction of IL‐13 triggers TGF‐beta1‐dependent tissue fibrosis in chronic 2,4,6‐trinitrobenzene sulfonic acid colitis
  publication-title: J Immunol.
– volume: 23
  start-page: 479
  year: 2005
  end-page: 490
  article-title: IL‐33, an interleukin‐1‐like cytokine that signals via the IL‐1 receptor‐related protein ST2 and induces T helper type 2‐associated cytokines
  publication-title: Immunity.
– volume: 41
  start-page: 114
  year: 2008
  end-page: 120
  article-title: Elevated levels of soluble ST2 protein in dengue virus infected patients
  publication-title: Cytokine.
– volume: 133
  start-page: 1295
  year: 2005
  end-page: 1304
  article-title: Inflammatory bowel disease: experience of two Chilean centers
  publication-title: Rev Med Chile.
– volume: 284
  start-page: 19420
  year: 2009
  end-page: 19426
  article-title: Interleukin‐33 is biologically active independently of caspase‐1 cleavage
  publication-title: J Biol Chem.
– volume: 258
  start-page: 301
  year: 1989
  end-page: 304
  article-title: A putative protein of a growth specific cDNA from BALB/c‐3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor
  publication-title: FEBS Lett.
– volume: 124
  start-page: 1206
  year: 2003
  end-page: 1214
  article-title: The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis
  publication-title: Chest.
– volume: 173
  start-page: 145
  year: 2004
  end-page: 150
  article-title: A novel therapy of murine collagen‐induced arthritis with soluble T1/ST2
  publication-title: J Immunol.
– volume: 15
  start-page: 562
  year: 1994
  end-page: 566
  article-title: The type II ‘decoy’ receptor: a novel regulatory pathway for interleukin 1
  publication-title: Immunol Today.
– volume: 40
  start-page: 216
  year: 2007
  end-page: 225
  article-title: Interleukin (IL)‐33 induces the release of pro‐inflammatory mediators by mast cells
  publication-title: Cytokine.
– volume: 235
  start-page: 474
  year: 1997
  end-page: 478
  article-title: Expression of ST2, an interleukin‐1 receptor homologue, is induced by proinflammatory stimuli
  publication-title: Biochem Biophys Res Commun.
– volume: 173
  start-page: 1229
  year: 2008
  end-page: 1242
  article-title: Nuclear interleukin‐33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation
  publication-title: Am J Pathol.
– volume: 264
  start-page: 14
  year: 1999
  end-page: 18
  article-title: Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT‐7/GM
  publication-title: Biochem Biophys Res Commun.
– volume: 87
  start-page: 971
  year: 2007
  end-page: 978
  article-title: IL‐33 can promote survival, adhesion and cytokine production in human mast cells
  publication-title: Lab Invest.
– volume: 19
  start-page: 5
  issue: suppl A
  year: 2005
  end-page: 36
  article-title: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
  publication-title: Can J Gastroenterol.
– volume: 37
  start-page: 1302
  year: 2007
  end-page: 1312
  article-title: T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation
  publication-title: Eur J Immunol.
– volume: 104
  start-page: 18660
  year: 2007
  end-page: 18665
  article-title: IL‐1 receptor accessory protein is essential for IL‐33‐induced activation of T lymphocytes and mast cells
  publication-title: Proc Natl Acad Sci USA.
– volume: 387
  start-page: 218
  year: 2009
  end-page: 222
  article-title: Mature interleukin‐33 is produced by calpain‐mediated cleavage in vivo
  publication-title: Biochem Biophys Res Commun.
– volume: 369
  start-page: 1627
  year: 2007
  end-page: 1640
  article-title: Inflammatory bowel disease: cause and immunobiology
  publication-title: Lancet.
– volume: 57
  start-page: 25
  year: 2009
  end-page: 29
  article-title: Secretion of soluble ST2—possible explanation for systemic immunosuppression after heart surgery
  publication-title: Thorac Cardiovasc Surg.
– volume: 351
  start-page: 940
  year: 2006
  end-page: 946
  article-title: Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury
  publication-title: Biochem Biophys Res Commun.
– volume: 52
  start-page: 1458
  year: 2008
  end-page: 1465
  article-title: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure
  publication-title: J Am Coll Cardiol.
– volume: 60
  start-page: 738
  year: 2009
  end-page: 749
  article-title: Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis
  publication-title: Arthritis Rheum.
– volume: 180
  start-page: 2443
  year: 2008
  end-page: 2449
  article-title: IL‐33, a potent inducer of adaptive immunity to intestinal nematodes
  publication-title: J Immunol.
– volume: 205
  start-page: 339
  year: 2008
  end-page: 346
  article-title: IL‐33 reduces the development of atherosclerosis
  publication-title: J Exp Med.
– volume: 282
  start-page: 26369
  year: 2007
  end-page: 26380
  article-title: Soluble ST2 blocks interleukin‐33 signaling in allergic airway inflammation
  publication-title: J Biol Chem.
– volume: 104
  start-page: 282
  year: 2007
  end-page: 287
  article-title: IL‐33, the IL‐1‐like cytokine ligand for ST2 receptor, is a chromatin‐associated nuclear factor in vivo
  publication-title: Proc Natl Acad Sci USA.
– volume: 284
  start-page: 1104
  year: 2001
  end-page: 1108
  article-title: Identification of human ST2 protein in the sera of patients with autoimmune diseases
  publication-title: Biochem Biophys Res Commun.
– volume: 136
  start-page: 367
  year: 2008
  end-page: 375
  article-title: [Inflammatory bowel diseases: an immunological approach.]
  publication-title: Rev Med Chil.
– volume: 179
  start-page: 772
  year: 2009
  end-page: 781
  article-title: Resolution of allergic inflammation and AHR is dependent upon disruption of the T1/ST2‐IL‐33 pathway
  publication-title: Am J Respir Crit Care Med.
– volume: 30
  start-page: 1468
  year: 2004
  end-page: 1473
  article-title: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma
  publication-title: Intensive Care Med.
– volume: 113
  start-page: 1490
  year: 2004
  end-page: 1497
  article-title: Nonclassical CD1d‐restricted NK T cells that produce IL‐13 characterize an atypical Th2 response in ulcerative colitis
  publication-title: J Clin Invest.
– volume: 31
  start-page: 84
  year: 2009
  end-page: 98
  article-title: Suppression of interleukin‐33 bioactivity through proteolysis by apoptotic caspases
  publication-title: Immunity.
– volume: 20
  start-page: 33
  year: 2009
  end-page: 38
  article-title: Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis
  publication-title: Eur Cytokine Netw.
– volume: 106
  start-page: 9021
  year: 2009
  end-page: 9026
  article-title: The IL‐1‐like cytokine IL‐33 is inactivated after maturation by caspase‐1
  publication-title: Proc Natl Acad Sci USA.
– volume: 164
  start-page: 277
  year: 2001
  end-page: 281
  article-title: Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation
  publication-title: Am J Respir Crit Care Med.
– volume: 14
  start-page: 1004
  year: 2009
  end-page: 1016
  article-title: Transcriptomic and genetic studies identify IL‐33 as a candidate gene for Alzheimer's disease
  publication-title: Mol Psychiatry.
– volume: 31
  start-page: 84
  year: 2009
  ident: 2025060906215214600_R36-7
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2009.05.007
– volume: 173
  start-page: 1229
  year: 2008
  ident: 2025060906215214600_R27-7
  publication-title: Am J Pathol.
  doi: 10.2353/ajpath.2008.080014
– volume: 351
  start-page: 940
  year: 2006
  ident: 2025060906215214600_R21-7
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1016/j.bbrc.2006.10.166
– volume: 57
  start-page: 25
  year: 2009
  ident: 2025060906215214600_R19-7
  publication-title: Thorac Cardiovasc Surg.
  doi: 10.1055/s-2008-1039044
– volume: 40
  start-page: 216
  year: 2007
  ident: 2025060906215214600_R25-7
  publication-title: Cytokine.
  doi: 10.1016/j.cyto.2007.09.013
– volume: 282
  start-page: 26369
  year: 2007
  ident: 2025060906215214600_R20-7
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M704916200
– volume: 30
  start-page: 1468
  year: 2004
  ident: 2025060906215214600_R9-7
  publication-title: Intensive Care Med.
  doi: 10.1007/s00134-004-2184-x
– volume: 15
  start-page: 562
  year: 1994
  ident: 2025060906215214600_R26-7
  publication-title: Immunol Today.
  doi: 10.1016/0167-5699(94)90217-8
– volume: 180
  start-page: 2443
  year: 2008
  ident: 2025060906215214600_R32-7
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.180.4.2443
– volume: 104
  start-page: 282
  year: 2007
  ident: 2025060906215214600_R12-7
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0606854104
– volume: 106
  start-page: 9021
  year: 2009
  ident: 2025060906215214600_R33-7
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0812690106
– volume: 37
  start-page: 1302
  year: 2007
  ident: 2025060906215214600_R15-7
  publication-title: Eur J Immunol.
  doi: 10.1002/eji.200636520
– volume: 14
  start-page: 1004
  year: 2009
  ident: 2025060906215214600_R16-7
  publication-title: Mol Psychiatry.
  doi: 10.1038/mp.2009.10
– volume: 87
  start-page: 971
  year: 2007
  ident: 2025060906215214600_R30-7
  publication-title: Lab Invest.
  doi: 10.1038/labinvest.3700663
– volume: 369
  start-page: 1627
  year: 2007
  ident: 2025060906215214600_R1-7
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(07)60750-8
– volume: 164
  start-page: 277
  year: 2001
  ident: 2025060906215214600_R5-7
  publication-title: Am J Respir Crit Care Med.
  doi: 10.1164/ajrccm.164.2.2008120
– volume: 235
  start-page: 474
  year: 1997
  ident: 2025060906215214600_R24-7
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1006/bbrc.1997.6810
– volume: 113
  start-page: 1490
  year: 2004
  ident: 2025060906215214600_R28-7
  publication-title: J Clin Invest.
  doi: 10.1172/JCI19836
– volume: 124
  start-page: 1206
  year: 2003
  ident: 2025060906215214600_R6-7
  publication-title: Chest.
  doi: 10.1378/chest.124.4.1206
– volume: 179
  start-page: 772
  year: 2009
  ident: 2025060906215214600_R14-7
  publication-title: Am J Respir Crit Care Med.
  doi: 10.1164/rccm.200805-666OC
– volume: 104
  start-page: 18660
  year: 2007
  ident: 2025060906215214600_R29-7
  publication-title: Proc Natl Acad Sci USA.
  doi: 10.1073/pnas.0705939104
– volume: 23
  start-page: 479
  year: 2005
  ident: 2025060906215214600_R11-7
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2005.09.015
– volume: 69
  start-page: 406
  year: 2006
  ident: 2025060906215214600_R37-7
  publication-title: Acta Gastroenterol Belg.
– volume: 387
  start-page: 218
  year: 2009
  ident: 2025060906215214600_R34-7
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1016/j.bbrc.2009.07.018
– volume: 60
  start-page: 738
  year: 2009
  ident: 2025060906215214600_R13-7
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.24305
– volume: 52
  start-page: 1458
  year: 2008
  ident: 2025060906215214600_R7-7
  publication-title: J Am Coll Cardiol.
  doi: 10.1016/j.jacc.2008.07.042
– volume: 136
  start-page: 367
  year: 2008
  ident: 2025060906215214600_R2-7
  publication-title: Rev Med Chil.
  doi: 10.4067/S0034-98872008000300014
– volume: 41
  start-page: 114
  year: 2008
  ident: 2025060906215214600_R8-7
  publication-title: Cytokine.
  doi: 10.1016/j.cyto.2007.11.001
– volume: 258
  start-page: 301
  year: 1989
  ident: 2025060906215214600_R4-7
  publication-title: FEBS Lett.
  doi: 10.1016/0014-5793(89)81679-5
– volume: 284
  start-page: 1104
  year: 2001
  ident: 2025060906215214600_R23-7
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1006/bbrc.2001.5090
– volume: 178
  start-page: 5859
  year: 2007
  ident: 2025060906215214600_R31-7
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.178.9.5859
– volume: 284
  start-page: 19420
  year: 2009
  ident: 2025060906215214600_R35-7
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M901744200
– volume: 173
  start-page: 145
  year: 2004
  ident: 2025060906215214600_R18-7
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.173.1.145
– volume: 264
  start-page: 14
  year: 1999
  ident: 2025060906215214600_R10-7
  publication-title: Biochem Biophys Res Commun.
  doi: 10.1006/bbrc.1999.1469
– volume: 19
  start-page: 5
  year: 2005
  ident: 2025060906215214600_R22-7
  publication-title: Can J Gastroenterol.
  doi: 10.1155/2005/269076
– volume: 20
  start-page: 33
  year: 2009
  ident: 2025060906215214600_R3-7
  publication-title: Eur Cytokine Netw.
  doi: 10.1684/ecn.2009.0142
– volume: 205
  start-page: 339
  year: 2008
  ident: 2025060906215214600_R17-7
  publication-title: J Exp Med.
  doi: 10.1084/jem.20071868
– volume: 133
  start-page: 1295
  year: 2005
  ident: 2025060906215214600_R38-7
  publication-title: Rev Med Chile.
SSID ssj0020209
Score 2.4167228
Snippet BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The...
Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL‐33 membrane receptor and belongs to the IL‐1R family....
ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble...
Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family....
SourceID proquest
pubmed
crossref
wiley
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1097
SubjectTerms Adolescent
Adult
Aged
Blotting, Western
Case-Control Studies
Colitis, Ulcerative - genetics
Colitis, Ulcerative - metabolism
Crohn Disease - genetics
Crohn Disease - metabolism
Crohn's disease
Female
Humans
IL‐33
inflammatory bowel disease
Interleukin-1 Receptor-Like 1 Protein
Interleukin-33
Interleukins - genetics
Interleukins - metabolism
Intestinal Mucosa - metabolism
Intestinal Mucosa - pathology
Male
Middle Aged
Receptors, Cell Surface - genetics
Receptors, Cell Surface - metabolism
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - genetics
ST2
ulcerative colitis
Young Adult
Title Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fibd.21175
https://www.ncbi.nlm.nih.gov/pubmed/20014018
https://www.proquest.com/docview/733331339
https://www.proquest.com/docview/745642098
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlRAXaHkuLSsLceCS3azz2EQ9dbcgQIAQD2kPSFHsjKUVkCB2FyRO_Qn9jf0lHdtJ2kUtQuSUxLbieGbsz57xZ4Ad0luBsfKdCBU6fqAiJxJCOb7ELAtckYXmHLKT0_Dgyj8aBIMZ-FrthbH8EPWCm7YM019rA0_FqP2HNHQoshbXRJPU_-pYLQ2IzmvqKJrTm_AOmt1o934cVaxCLm_XJafGoqn9bX_BzGnUaoad_SW4ripso01uWpOxaMnnF1yO7_yjj7BYwlH2zerPJ5jBfBnmT0qH-wpc92tCZ7tfkxWKEWZkefGIt-zikrcPj3_9-Ol5zHJCs2HOSq7WEdOLvPRCkdbdGW8-E8UTFSu9Qqtwtb932T9wygMZHOlzN3CEjLEreEaoR3mdkCshPQxcqQIeYZyGJFpCgGHqpZjRox-7WRgRQksJl5CdK28N5vIixw1gAdL4iChRE_gFMkw7krRDEYJQimY4vAG7lWgSWbKV60MzbhPLs8wTaq3EtFYDtuus95ai41-Ztki-r6WzSvIJGZj2mqQ5FpNR0vXoopl8_EoWzclD-hY1YN0qTf0hbgiMOpSya0T__xokh73v5mbz7Vk_w4KNZtDhw19gbvwwwS0CSWPRhNnuoNuED72907PzprGN3_wfDpM
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED-NIo29wDbY6GDMmvawl7Sp86eJxAtsTO3W9mF00h5AUeycpYmSINqCtCc-Ap-RT8LZTrIVbdVEnpLYURzfXfw7n_07gAPSW4Gx8p0IFTp-oCInEkI5vsQsC1yRhSYP2XAU9i7808vgcgXeVnthLD9EPeGmLcP8r7WB6wnp9g1r6JXIWlwzTT6Cxzqjt3GozmvyKPLqzQIP8m90gD-OKl4hl7frRxdGo4UdbreA5iJuNQPPyTP4XDXZrjf50prPREte_8Pm-L_ftA5PS0TK3lkV2oAVzDdhdVjG3J_Dp6Oa09lu2WSFYgQbWV78wAn7OObt_uDPr9-exywtNLvKWUnXOmV6npduKFK8ryagz0Txkx4rA0Mv4OLkw_io55Q5GRzpczdwhIyxK3hGwEd5nZArIT0MXKkCHmGchiRdAoFh6qWY0aUfu1kYEUhLCZqQqStvCxp5keNLYAHSEIkoUXP4BTJMO5IURBGIUIqcHN6Ew0o2iSwJy3XejEliqZZ5Qr2VmN5qwn5d9Ztl6bir0i4JeFk5q0SfkI3pwEmaYzGfJl2PDnLm4yVVNC0PKVzUhG2rNfWLuOEw6lDJoZH9_S1I-u-PzcnOw6vuwZPeeDhIBv3R2StYs4sb9Gri19CYfZ_jLmGmmXhjTOMv96EQLQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED9tQ6r2Mv6MsQIDa9pDX9Kmzp8m4glWqnZsE4JO6kOlKHbOUkWXTGsLEk98BD4jn4SznQQ6wTQtT0l8URzfXfw7n_0zwBHZrcBY-U6ECh0_UJETCaEcX2KWBa7IQrMP2dl5OLzwTybBZAPeVGthLD9EPeCmPcP8r7WDX2Wq84c0dCayNtdEk5vwwA_dSJt0_1PNHUVBvZnfQeGNzu_HUUUr5PJO_ehaZ7S2wO0vnLkOW02_M3gI06rGdrrJl_ZqKdry-w0yx3t-0iPYKfEoe2sN6DFsYP4EGmdlxn0Xpsc1o7NdsMkKxQg0srz4inP2ecw7o9NfP356HrOk0GyWs5KsdcH0KC_dUGR2lyadz0TxjR4r00JP4WLwfnw8dModGRzpczdwhIyxJ3hGsEd53ZArIT0MXKkCHmGchqRbgoBh6qWY0aUfu1kYEURLCZiQoytvD7byIsd9YAFSB4koUTP4BTJMu5LMQxGEUIpCHN6EVqWaRJZ05XrXjHliiZZ5Qq2VmNZqwmEtemU5Ov4ldED6va2cVZpPyMN02iTNsVgtkp5HB4Xy8S0impSH7C1qwjNrNPWLuGEw6lJJy6j-_zVIRu_65uT53UVfQ-Njf5Ccjs4_vIBtO7NBTyV-CVvL6xUeEGBailfGMX4D16cO5Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+the+novel+ST2%2FIL-33+system+in+patients+with+inflammatory+bowel+disease&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Beltr%C3%A1n%2C+Caroll+J&rft.au=N%C3%BA%C3%B1ez%2C+Luc%C3%ADa+E&rft.au=D%C3%ADaz-Jim%C3%A9nez%2C+David&rft.au=Farfan%2C+Nancy&rft.date=2010-07-01&rft.eissn=1536-4844&rft.volume=16&rft.issue=7&rft.spage=1097&rft_id=info:doi/10.1002%2Fibd.21175&rft_id=info%3Apmid%2F20014018&rft.externalDocID=20014018
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon